RxDoctor Payments DataLook up a doctor →

Edward Leroy, MD

Spinal Cord Injury Medicine · Fresno, CANPI 1508992660

Payments from drug & device makers

$12,177in general payments, 2019–2025

Across 608 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$683
  • Medtronic$559
  • Pfizer$503
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$12,177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few spinal cord injury medicine providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$124,250
Medicare patients
235
Services billed
3,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl96$121,255
BelbucaBuprenorphine Hcl151$110,052
Xtampza ErOxycodone Myristate129$80,926
Buprenorphine230$64,739
NucyntaTapentadol Hcl51$51,282
RelistorMethylnaltrexone Bromide22$50,840
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,340$38,369
OxycontinOxycodone Hcl51$37,036
LinzessLinaclotide50$35,882
UbrelvyUbrogepant11$30,486
MovantikNaloxegol Oxalate46$29,219
RexultiBrexpiprazole13$21,101
QuliptaAtogepant13$17,741
Oxymorphone Hcl ErOxymorphone Hcl24$14,891
Oxycodone Hcl528$13,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca, Xtampza Er, Nucynta$2,599$363,515427 claims
AbbVieLinzess, Ubrelvy, Qulipta$1,361$84,10974 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,606$50,84022 claims
Redhill Biopharma Inc.Movantik$105$29,21946 claims
Otsuka America Pharmaceutical, Inc.Rexulti$179$21,10113 claims
MerckBelsomra$343$11,29227 claims
Eisai Inc.Dayvigo$442$9,79523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few spinal cord injury medicine providers in Californiaon file to place this against a meaningful peer group, so we don't.

Other spinal cord injury medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →